Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
An interview with Sergey Malashikhin of Bachem on what’s behind the manufacturing of complex APIs.
Released By Bachem
May 31, 2023
There is more to creating APIs for generics than simply following a recipe. The support and services around the molecules are critical. Customers need to be able to rely on passion and expertise to offer all the ingredients for a successful API supply experience and successful launch, and make generics accessible and affordable to patients all over the world. Going the extra mile helps to stand out in the competitive generics landscape. Customers can focus on their masterpiece, while CDMOs like us are taking care of the rest! Read the interview from Sergey Malashikhin to learn more on what’s behind the manufacturing of complex APIs. The generics space is a very dynamic and growing market. What are the challenges that face the generics landscape? “The main challenges that generics companies face are to deliver the right products, at the right time, and at the right cost while thoroughly monitoring product safety. Therefore, it is of the utmost importance that you find the right partner to help your business to successfully deliver the generic masterpiece. It is well known, that it needs more to create active pharmaceutical ingredients (APIs) for generics than than simply following a recipe, especially for complex APIs. The expertise and support services around the molecule are critical to ensure a successful launch. Having this in mind customers need to be accompanied throughout the whole process from manufacturing to regulatory and delivery.” What does a CDMO like Bachem offer to meet these challenges? “These challenges aren’t typically solved by a single service offering, but through a multidisciplinary approach, which enhances commercial success through innovation and operational excellence and manages risk, regulatory, and compliance issues. With more than 50 years of experience, we have built outstanding regulatory expertise to provide a complete generic API package to meet your needs. Innovation is imperative to continuously improve our processes, and thus their efficiency. Exploring new technologies to meet emerging generic API opportunities at high quality, minimized lead time, and the right cost. Providing customers with a full package for generic APIs to answer their needs: ● Extensive and evolving catalog ● Comprehensive documentation ● Regulatory know-how ● The right scale for you – with reliable timely delivery from mg to tonnes ● Some of our starting materials are manufactured internally Understanding this and going the extra mile to offer comprehensive services and an all-around positive experience for customers is key.” Among the complex peptide API portfolio, GLP-1 analogs like liraglutide or semaglutide are currently of high interest in the generics market. How do you ensure an efficient and high-quality production of these molecules? “Originally, liraglutide and semaglutide are produced at industrial scale using genetically modified organisms – the so-called recombinant method. With decades of experience in peptide synthesis, we were able to develop a robust and scalable commercial GMP process to manufacture them synthetically via solid-phase peptide synthesis (SPPS). This process combined with quality by design approach and efficient purification methods, we obtain these APIs with high purity and minimized batch-to-batch variations. With this, ensuring a strict control of every individual impurity and aggregation behaviour. Then, the sameness of the generic API with the original drug substance is proved with a combination of multiple sophisticated orthogonal analytical methods. It allows making a detailed comparison with the reference listed drugs followed by immunogenicity and toxicological studies for individual impurities.” Sergey Malashikhin on generic active pharmaceutical ingredients such as liraglutide and other GLP-1 analogues. What part has innovation in the generic development? “Innovation is a strategic pillar at Bachem. Innovation enables us to keep a technological leadership and offer customers world-class products and services. Being future-oriented is also what will help customers to remain competitive in the generic world. So, we are constantly assessing and developing 2nd generation processes for our generics. We are increasing process efficiency, implementing the latest manufacturing and purification technologies to deliver large-scale quantities at a competitive price, yet without jeopardizing product quality and continuing to stay in line with the strictest regulatory guidelines. Your product quality and patient safety always comes first.” With more and more stringent requirements from authorities, how does Bachem ensure the successful filing of generics APIs? “The FDA has issued very demanding guidelines for the development of certain highly purified synthetic peptides. To ensure compliance, a unique in-house expertise is a key asset in the complex APIs development. As explained earlier, we are in the very good position where we can offer GMP material of excellent quality and no signs of aggregation behaviour, especially the latter being a common issue with GLP-1 analogues. You can select a full package of services around the generic API and there are more than 80 DMFs available worldwide. The regulatory affairs experts are highly experienced and communicate with authorities on a regular basis. We do everything to ensure a smooth registration process for your final drug product.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !